A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
NCT ID: NCT06779773
Last Updated: 2026-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1000 participants
OBSERVATIONAL
2025-01-22
2030-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Avacincaptad pegol can help slow down the worsening or progression of geographic atrophy. Avacincaptad pegol is a treatment approved in the US to treat geographic atrophy.
This study is about collecting information on how people with geographic atrophy are treated in routine clinical practice. This includes recording any medical problems from avacincaptad pegol. This is known as an observational study. Information will be collected from the peoples' medical records during and after treatment. The people in this study will have geographic atrophy in 1 or both eyes and they and their doctor has decided they will be treated with avacincaptad pegol. The individual's doctor decides on treatment, not the study sponsor (Astellas).
People that want to take part in the study will have eye examinations that they would usually have as part of their routine care. People will also be asked to complete surveys about their eye health. These surveys will occur when treatment starts and then every 6 months for the first 2 years. After 2 years the surveys will happen once a year. The people on the study can take part if their doctor provides treatment with avacincaptad pegol and they want to continue with the study. The people on the study can take part for up to 3 years or up to 5 years, depending on when they start the study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase II/III Study of Anti-VEGF in Neovascular AMD
NCT00021736
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
NCT06722157
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06961370
Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)
NCT00088192
Intravitreal Aflibercept for Submacular Hemorrhage
NCT03169660
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Izervay
Patients with geographic atrophy (GA) secondary to AMD who have made decision to begin treatment with Izervay
Avacincaptad pegol (ACP)
intravitreal injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Avacincaptad pegol (ACP)
intravitreal injection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with a decision to treat with intravitreal avacincaptad pegol (ACP) prior to enrollment
* Patient willingness to complete the patient reported outcome (PRO).
Exclusion Criteria
* Active ocular or peri-ocular infection in either eye
* Active, suspected intraocular inflammation in either eye at enrollment/baseline visit
* Hypersensitive to ACP or to any ingredient in the formulation
* Patients currently participating in an investigational program with interventions outside of routine clinical practice.
* Patients who have received ACP in the study eye. Note: Patients who have received or are receiving ACP in the fellow eye are eligible to be included in the study.
* Patients who have received any intravitreal complement inhibitor other than ACP in either eye. Note: Patients who have received an intravitreal complement inhibitor other than ACP in either eye and have completed the 90-day washout period are eligible to be included in the study.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Global Development, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Astellas Pharma Global Development, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Phoenix Retina Clinical Trials, LLC
Phoenix, Arizona, United States
Retinal Consultants of AZ
Phoenix, Arizona, United States
Retina Macula Institute of Arizona
Scottsdale, Arizona, United States
The Retina Partners
Encino, California, United States
Harvard Eye Associates
Laguna Hills, California, United States
Retina Consultants of Southern CA
Redlands, California, United States
Retinal Consultants Medical Group Inc
Sacramento, California, United States
Retina Macula Institute
Torrance, California, United States
Rocky Mountain Lions Eye Institute
Aurora, Colorado, United States
Retina Consultants of Southern Colorado
Colorado Springs, Colorado, United States
Colorado Retina Associates, PLLC
Lakewood, Colorado, United States
Florida Eye Clinic
Altamonte Springs, Florida, United States
Advanced Retina Institute
Bonita Springs, Florida, United States
University of Miami
Coral Gables, Florida, United States
Retina Care Specialists
Palm Beach Gardens, Florida, United States
Eye Physicians of Pinellas PA dba Eye Institute of West Florida
Tampa, Florida, United States
Retina Specialists of Tampa
Wesley Chapel, Florida, United States
Southeast Retina Center, P.C.
Augusta, Georgia, United States
University Retina and Macula Associates, P.C.
Oak Forest, Illinois, United States
Illinois Retina Associates
Oak Park, Illinois, United States
Illinois Eye Center
Peoria, Illinois, United States
Wolfe Eye Clinic
West Des Moines, Iowa, United States
Cumberland Valley Retina Consultants,P.C.
Hagerstown, Maryland, United States
Retina Specialists
Towson, Maryland, United States
Retina Associates of Michigan
Grand Blanc, Michigan, United States
Retina Consultants of Minnesota PLLC
Saint Louis Park, Minnesota, United States
Mississippi Retina Associates
Madison, Mississippi, United States
Deep Blue Retina Clinical Research
Southaven, Mississippi, United States
Eye Associates of North Jersey PA
Dover, New Jersey, United States
NJ Retina
Edison, New Jersey, United States
NJ Retina
Lakewood, New Jersey, United States
Monmouth Retina Consultants
Little Silver, New Jersey, United States
NJ Retina
Toms River, New Jersey, United States
SightMD
Brentwood, New York, United States
Retina-Vitreous Surgeons of Central NY
Liverpool, New York, United States
NY Retina Ophthalmology PLLC
Massapequa, New York, United States
Retina Associates of New York
New York, New York, United States
Long Island Vitreoretinal Consultants
Scarsdale, New York, United States
Vitreoretinal Consultants
Shirley, New York, United States
North Carolina Retina Associates
Cary, North Carolina, United States
North Carolina Retina Associates
Wake Forest, North Carolina, United States
The Ohio State University
Columbus, Ohio, United States
CEI Physicians PSC, LLC dba
Dayton, Ohio, United States
Verum Research, LLC
Eugene, Oregon, United States
Erie Retina Research
Erie, Pennsylvania, United States
Southeastern Retina Associates, P.C.
Knoxville, Tennessee, United States
Southeastern Retina Associates, P.C.
Knoxville, Tennessee, United States
Mid South Retina Associates
Memphis, Tennessee, United States
Tennessee Retina, PC
Nashville, Tennessee, United States
Retina Research Institute of Texas
Abilene, Texas, United States
Retina of North Texas
Dallas, Texas, United States
Retina & Vitreous of Texas
Houston, Texas, United States
Valley Retina Institute
McAllen, Texas, United States
Medical Center Ophthalmology Associates
San Antonio, Texas, United States
Retina Associates of Utah, P.C.
Murray, Utah, United States
Salt Lake Retina
Salt Lake City, Utah, United States
The Retina Group of Washington
Fairfax, Virginia, United States
Piedmont Eye Center, Inc.
Lynchburg, Virginia, United States
Virginia Retina Center
Warrenton, Virginia, United States
Retina & Vitreous Consultants of Wisconsin
Greenfield, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3021-MA-3543
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.